Dallas, TX 1/29/2008 2:07:26 AM
News / Finance

A New Solution for Early Detection of Breast Cancer Proposed by Neoprobe Corporation

To read the complete article, please visit http://www.beaconequityresearch.com/ – Click on News and Commentary

 

According to the American Cancer Society, 7.6 million people died from cancer in the world during 2007. Worldwide, one in three people will develop cancer and one in four people will die of cancer. Cancer is the leading cause of death among Americans under the age of 85.

 

Breast cancer affects one in eight women during their lives. Worldwide, breast cancer is the fifth most common cause of cancer death. In 2005, breast cancer caused 502,000 deaths worldwide or almost 1% of all deaths. In the United States, breast cancer is the third most common cause of cancer death. In 2007, breast cancer is expected to cause 41,000 deaths nationally. In an attempt to find unsuspected cancers the medicine used is breast cancer screening. The most common screening methods are self and clinical breast exams, x-ray mammography, breast magnetic resonance imaging, ultrasound, genetic testing and Breast-Specific Gamma Imaging, used by NEOP. As for melanoma cancer, around 160,000 new cases of melanoma are diagnosed worldwide each year.

 

For many years, researchers have tried to find out cancer causes and solutions for cancer diagnosis and treatment. There are many private companies, alongside with public institutions involved in this process.     

 

Neoprobe Corporation (NEOP) is focused on improving cancer surgery outcomes by using gamma detection devices in combination with radiopharmaceutical agents, also referred to as “tracing” or “targeting” agents. The Company’s main product, neo2000® Gamma Detection Systems, utilizes a radioactive tracing agent, which is injected directly into the tumor site. The agent then follows the same flow along the lymphatic system that a tumor would follow if it metastasized or spread. The operative surgeon can then track this flow with a special probe identifying key lymph nodes along the path to be tested for the presence of cancer.

 

To read the complete article, please visit http://www.beaconequityresearch.com/ – Click on News and Commentary

 

Beacon Equity Research Volume Leaders Intel (Nasdaq: INTC), Sirius Satellite (Nasdaq: SIRI), Cisco Systems (Nasdaq: CSCO), Apple Inc (Nasdaq: AAPL), Yahoo Inc. (Nasdaq: YHOO), and Microsoft (Nasdaq: MSFT).